PD-1 Inhibitors in Oncology

PD-1 Inhibitors in Oncology

• May 30, 2016
• Reading time: 2 minutes

Currently, immune checkpoint inhibitors developed by Ono Pharmaceutical and Merck & Co. are undergoing rigorous clinical evaluation at numerous medical institutions globally. In the United States and Japan, these agents have received regulatory approval for specific oncological indications. Due to their primary mechanism of action, they are commonly referred to as PD-1 inhibitors. In a physiological state, the PD-1 (Programmed Cell Death Protein 1) pathway serves as a critical checkpoint to prevent the immune system from attacking healthy cells; however, malignant cells frequently exploit this pathway to evade immunosurveillance and avoid immune-mediated destruction.

The therapeutic efficacy of these monoclonal antibodies lies in their ability to block the inhibitory signals of the immune response, thereby restoring the T-cell's anti-tumor activity. CTLA-4 (Cytotoxic T-Lymphocyte Associated Protein 4) represents another significant therapeutic target within this class of inhibitors. Currently, agents such as Nivolumab and Ipilimumab are commercially available, and specialized applications for access can be facilitated in various regions including Taiwan. Generally, unless supported by robust clinical data for specific indications, PD-1 inhibitors are often not utilized as first-line therapy. Regarding combination regimens, there is increasing clinical evidence for the concurrent administration of chemotherapy and PD-1 inhibitors. However, since patient profiles and clinical conditions vary significantly, the appropriateness of such regimens must be determined through professional medical assessment. Patients are advised to strictly adhere to the guidance of their oncology specialists.

Notably, Professor Tasuku Honjo of Kyoto University, a recipient of the Tang Prize (and later the Nobel Prize in Physiology or Medicine), has provided a comprehensive explanation of the molecular mechanisms underlying this discovery. The following is a specialized excerpt summarizing these findings.

For the full detailed report, please refer to the official documentation.

T-cells play a central role in adaptive immunity; however, their activation is contingent upon the recognition of foreign or pathological antigens processed and presented by antigen-presenting cells (APCs). This process is precisely regulated by a complex array of co-stimulatory and co-inhibitory molecules. While certain molecules promote T-cell activation to ensure an effective response against pathogens, others serve inhibitory functions to prevent immune overactivation and tissue damage.

A group of regulatory proteins on the T-cell surface, known as the CD28 receptor family, is pivotal in this regulation. This family is divided into activating receptors that transmit stimulatory signals and inhibitory receptors that transmit inhibitory signals. Their corresponding ligands on APCs belong to the B7 family. Among the inhibitory receptors, the most prominent are Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Cell Death Protein 1 (PD-1). Their respective ligands on APCs or tumor cells are B7-1/B7-2 and PD-L1/PD-L2. These molecules are now recognized as "immune checkpoint" receptors and ligands.

Dysregulation of this sophisticated system can lead to various pathologies. For instance, insufficient inhibitory function may result in autoimmune diseases, where the immune system attacks host tissues. Conversely, cancer cells exploit "immune evasion" mechanisms, such as the overexpression of B7 family ligands (PD-L1) on their surface. This interaction with T-cell inhibitory receptors suppresses anti-tumor effects. Current research focuses on neutralizing these evasion pathways to enhance the immune system's intrinsic capacity to eradicate malignancy.

Source: Adapted from Tang Prize official materials.

Related to Immunotherapy

• Immunotherapy
  • (Solid Tumors) Clinical efficacy of Pembrolizumab (Keytruda)
  • (Solid Tumors) Rakuten Medical initiates Phase I clinical trial for RM-1995 photo-immunotherapy
  • (Lung Cancer) Therapeutic outcomes of Pembrolizumab (Keytruda)

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1